



ophthalmology  
futures forums

2022

**Euro *Hybrid* Forums**

**Retina Forum**

Weds. 31 Aug.

**The Fontenay Hotel  
Hamburg, Germany**

**Retina Programme**

2022



# Alcon

## We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years—and as the new Alcon, it's what guides our focus towards the brilliant future ahead.

Learn more at [alcon.com](https://alcon.com)

### CONNECT WITH US!

 @AlconEyeCare  
@AlconCareers

 @Alcon

 @AlconLife

## Welcome: RETINA HYBRID FORUM

### Welcome to Ophthalmology Futures Retina Forum 2022.

After two years of virtual meetings, we are pleased to be in Hamburg for an in-person event on the 10 th Anniversary of Ophthalmology Futures Forums. Our universe has certainly changed in many ways over the past two years, perhaps no greater than in how people communicate information. While it would be wonderful to have every attendee join us in Hamburg, we realize this is not possible and thus there will be a virtual component to the meeting for those who prefer to participate remotely from other locations in Europe and the rest of the world.

Retina innovation has never been more exciting and we received a record number of applications of which 21 companies have been selected to present at the 2022 Forum. Our 7 panels, which feature an all-star cast of leaders and stakeholders in retina innovation, will cover advances in Gene Therapy, Geographic Atrophy,

Artificial Intelligence, Vitreo-retinal Surgery, as well as new approaches to address Neovascular Age Related Macular Degeneration and Diabetic Retinopathy including some that utilize novel drug delivery methods. There have been several notable success stories in the retina arena over the past decade and we will hear from leading investors on the degree of optimism with regard to future investment to address unmet need in this space. We are confident that you will enjoy the formal program as well as the networking opportunities that come with an in-person event.

Ophthalmology Futures Forums would like to thank our key advisors, corporate presenters and distinguished faculty for their invaluable support and assistance. We would also like to especially thank our sponsors who have provided support allowing us to keep registration costs low for all attendees!

Thank you for joining us in Hamburg!

**Keith Barton and Kuldev Singh**  
on behalf of the Ophthalmology Futures Team



Vision Futures Limited, London, UK.  
Registered in England No: 8125858.

# Timings:

## RETINA HYBRID FORUM

TIMINGS ARE IN CENTRAL EUROPEAN SUMMER TIME

**12:00 - 12:40**

### REGISTRATION & LIGHT LUNCH

Sponsored by InFocus Clinical Research

**12:40 - 12:50**

### WELCOME

- Keith Barton and Kuldev Singh

**12:50 - 13:20**

### PANEL 1: BEYOND ANTI-VEGF THERAPY FOR NEOVASCULAR AMD AND DIABETIC RETINOPATHY - HYPE VS REALITY

#### PANEL

- Naveed Shams
- David Bingaman
- Jason Ehrlich
- Gemmy Cheung
- David Silverman
- Georges Weissgerber

#### CHAIR

- Francesco Bandello

**13:20 - 13:50**

### PANEL 2: AI AND DIGITAL HEALTH FOR POSTERIOR SEGMENT DISEASE - ARE WE THERE YET?

#### PANEL

- Georgy Shakirin
- Gustavo De Moraes
- Arthur Ciociola
- Helge Sudkamp
- Kester Nahen
- Holger Lubatschowski
- Dawn Sim

#### CO-CHAIRS

- Adnan Tufail
- Ursula Schmidt-Erfurth

**13:50 - 15:00**

### COMPANY PRESENTATIONS 1

- Oculis | Riad Sherif
- Oxurion | Tom Graney
- OcuTerra Therapeutics | David Tanzer
- OcuPhire Pharma | Mina Sooch
- Visotec | Helge Sudkamp
- OCUMAX Healthcare | Holger Lubatschowski
- Notal Vision | Kester Nahen
- Deepeye Medical | Manuel Opitz
- Imagine Eyes | Nicolas Chateau
- RetinSight | Corinna zur Bonsen-Thomas
- Summary

**15:00 - 15:20**

### NETWORKING BREAK

Sponsored by InFocus Clinical Research

**15:20 - 15:30**

### PERSPECTIVE BY NANNA LÜNEBORG

**15:30 - 16:00**

### PANEL 3: INVESTMENT IN RETINA INNOVATION - IS THERE REASON TO BE OPTIMISTIC?

#### PANEL

- Anta Gkelou
- Ram Palanki
- Michael Giaquinto
- Begona Carreno
- Derrick Li
- Max Klement
- Caroline Stout

#### CHAIR

- Nanna Lüneborg

**16:00 - 16:30**

### PANEL 4: ALTERNATIVES TO INTRAVITREAL DRUG DELIVERY FOR POSTERIOR SEGMENT DISEASES

#### PANEL

- Thomas Ciulla
- Frederic Guerard
- Riad Sherif
- Eugene de Juan
- Merce Morral
- Michael O'Rourke

#### CHAIR

- Einar Stefánsson

**16:30 - 17:50**

### COMPANY PRESENTATIONS 2

- Clearside Biomedical | Thomas Ciulla
- Re-Vana Therapeutics | Michael O'Rourke
- Aavantgarde | Naveed Shams
- Nanoscope Therapeutics | Aaron Osborne
- Santen Cell and Gene Therapy | Marianthi Psacha
- Apellis Pharmaceuticals | Lukas Scheibler
- Endogena Therapeutics | Matthias Steger
- Iveric-Bio | Dhaval Desai
- Complement Therapeutics | Rafiq Hasan
- REGENXBIO | Ram Palanki
- Novartis Pharma | Jill Hopkins
- Summary

**17:50 - 18:20**

### NETWORKING BREAK

Sponsored by InFocus Clinical Research

**18:20 - 18:50**

### PANEL 5: GENE THERAPY PLATFORMS FOR MACULAR DISEASE - ARE THEY WORTH THE MONEY?

#### PANEL

- Dominik Fischer
- Victor Chong
- Aaron Osborne
- Sumie Takahara

#### CO-CHAIRS

- Bart Leroy
- José-Alain Sahel

**18:50 - 19:20**

### PANEL 6: WHAT IS EXCITING IN VITREO-RETINAL SURGERY?

#### PANEL

- Paul Hallen
- Robert Niemietz
- Marc de Smet
- Gavin Tan

#### CHAIR

- Paulo Eduardo Stanga

**19:20 - 19:50**

### PANEL 7: COMPLEMENT INHIBITION AND BEYOND FOR GEOGRAPHIC ATROPHY

#### PANEL

- Kourous Rezaei
- Pravin Dugel
- Federico Grossi
- Rafiq Hasan
- Christopher Brittain
- Jill Hopkins

#### CO-CHAIRS

- Sobha Sivaprasad
- Ramin Tadayoni

**19:50 - 20:00**

### Summary

Adnan Tufail

**20:00 - 20:05**

### CONCLUDING COMMENTS FROM THE CO-CHAIRS

- Keith Barton and Kuldev Singh

**20:05 - 21:00**

### RECEPTION

Sponsored by InFocus Clinical Research




## REGISTER FOR OUR 2022 EUROPEAN FORUM

Where:  
**Principe di Savoia, Milan, Italy**

When:  
**Thur. 15 Sept. 2022**

Register you place at:  
**[ophthalmology-futures.com/registration](https://ophthalmology-futures.com/registration)**



EssilorLuxottica is proud to  
support the Ophthalmology  
Futures Forums 2022.

Join the panel on myopia to learn more  
about the future of myopia management.

<https://www.ophthalmology-futures.com/euro-2022/>

Thursday, 15 September,  
16:10 - 16:40 CET

[essilorluxottica.com](https://www.essilorluxottica.com)




SEEKING TO  
IMPROVE LIVES  
THROUGH THE  
CURATIVE  
POTENTIAL OF  
GENE THERAPY

**OUR COMMITMENT**

REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy using our NAV® Technology Platform. Our gene therapy product candidates are designed to deliver functional genes, enabling the production of therapeutic proteins or antibodies that are intended to impact disease.

For the latest updates on our programs, visit [REGENXBIO.COM](https://www.regenxbio.com)

**REGENXBIO.com**

IVERIC  
BIO

TRANSFORMATIVE  
THERAPIES  
FOR RETINAL DISEASES

Retina is our focus. **Our only focus.**

Geographic Atrophy | Stargardt Disease | Inherited Retinal Diseases

Learn more at [IvericBio.com](https://www.IvericBio.com)

Envisioning the future

NOVARTIS | Reimagining Medicine



# Speakers: PANNELISTS & CHAIRS PRESENTING COMPANIES

## PANELLISTS & CHAIRS

### B

- **Francesco Bandello**  
Professor, University Vita-Salute
- **David Bingaman**  
Chief Development Officer, Ora Inc.
- **Christopher Brittain**  
Global Head of Ophthalmology, Genentech

### C

- **Begona Carreno**  
Global Head BDL Ophthalmology, Novartis Pharma AG
- **Gemmy Cheung**  
Ophthalmologist, Singapore National Eye Centre
- **Arthur Ciociola**  
Vice President Global Head Regulatory Affairs GDD Ophthalmology, Devices, & Innovation, Novartis Pharma AG
- **Thomas Ciulla**  
Chief Medical Officer and Chief Development Officer, Clearside Biomedical
- **Victor Chong**  
VP, Global Head of Retina, Janssen R&D

### D

- **Eugene de Juan**  
Managing Partner, ForSight Labs, LLC
- **Gustavo De Moraes**  
Chief Medical Officer, Ora Inc.
- **Marc de Smet**  
Director, Microinvasive Ocular Surgery - Retina and Inflammation
- **Pravin Dugel**  
President, IVERIC bio

### E

- **Jason Ehrlich**  
CMO/CFO, Kodiak Sciences, Inc.

### F

- **Dominik Fischer**  
Professor of Ophthalmology, University of Tuebingen

### G

- **Michael Giaquinto**  
Senior Managing Director, SVB Leerink
- **Anta Gkelou**  
Principal, Sofinnova Partners
- **Stratos Gotzaris**  
Vitreoretinal Specialist, My Retina Athens Eye Center
- **Federico Grossi**  
Chief Medical Officer, Apellis Pharmaceuticals
- **Frederic Guerard**  
CEO, Graybug Vision

### H

- **Paul Hallen**  
Vice President & Global Head, Retina, Alcon
- **Rafiq Hasan**  
CEO, Complement Therapeutics Ltd
- **Jill Hopkins**  
SVP, Global Head Ophthalmology Development, Novartis Pharma AG

### K

- **Max Klement**  
Principle, Novo Ventures

### L

- **Bart Leroy**  
Professor of Ophthalmology, Ghent University Hospital
- **Derrick Li**  
Managing Director, Healthcare, RW Baird
- **Holger Lubatschowski**  
CEO, OCUMAX Healthcare GmbH
- **Nanna Lüneborg**  
Partner, Forbion

### M

- **Merce Morral**  
Senior Global Group Medical Director, Port Delivery System, Roche-Genentech

### N

- **Kester Nahen**  
CEO, Notal Vision Ltd
- **Robert Niemietz**  
Sr. Director of Marketing, Bausch + Lomb

### O

- **Michael O'Rourke**  
CEO, Re-Vana Therapeutics
- **Aaron Osborne**  
CMO and CDO, Nanoscope Therapeutics, Inc.

### P

- **Ram Palanki**  
SVP, Commercial Strategy & Operations, REGENXBIO

### R

- **Kourous Rezaei**  
Associate Professor, Illinois Retina Associates

### S

- **José-Alain Sahel**  
Chairman, University of Pittsburgh
- **Ursula Schmidt-Erfurth**  
Professor and Director, Department of Ophthalmology and Optometry, Medical University Vienna
- **Naveed Shams**  
Chief Development and Medical Officer, AAVantegarde Bio
- **Georgy Shakirin**  
Head of Artificial Intelligence, ZEISS
- **Riad Sherif**  
CEO, Oculus SA

- **David Silverman**  
Group Clinical Director, Roche-Genentech
- **Dawn Sim**  
Medical Director, Genentech
- **Sobha Sivaprasad**  
Professor of Ophthalmology, UCL and Consultant Ophthalmologist, Moorfields Eye Hospital
- **Einar Stefánsson**  
Professor, University of Iceland
- **Paulo Eduardo Stanga**  
Professor of Ophthalmology, London Vision Clinic, Retina
- **Caroline Stout**  
Partner, EcoR1 Capital, LLC
- **Helge Sudkamp**  
CEO, Visotec GmbH

### T

- **Ramin Tadayoni**  
Professor of ophthalmology, Université de Paris, France and Head of Department, Lariboisière, Saint Louis and Adolphe de Rothschild Foundation Hospitals
- **Gavin Tan**  
Senior Consultant, Singapore National Eye Centre
- **Sumie Takahara**  
Director, Global Product & Market Planning, REGENXBIO
- **Adnan Tufail**  
Professor of Ophthalmology, Moorfields Eye Hospital NHS Trust

### W

- **Georges Weissgerber**  
Clinical Development Head, Ophthalmology Development Unit, Novartis Pharma AG

## PRESENTING COMPANIES

### A

- **Aavantgarde**  
Naveed Shams, Chief Development and Medical Officer
- **Apellis Pharmaceuticals**  
Lukas Scheibler, CIO

### C

- **Clearside Biomedical**  
Thomas Ciulla, CMO
- **Complement Therapeutics**  
Rafiq Hasan, CEO

### D

- **Deepeye Medical**  
Manuel Opitz, CEO

### E

- **Endogena Therapeutics**  
Matthias Steger, CEO, Co-Founder

### I

- **Imagine Eyes**  
Nicolas Chateau, CEO, Co-Founder
- **Iveric-Bio**  
Dhaval Desai, SVP & CDO

### O

- **Oculus**  
Riad Sherif, CEO
- **OCUMAX Healthcare**  
Holger Lubatschowski, CEO
- **Oxurion**  
Tom Graney, CEO
- **Ocuphire Pharma**  
Mina Sooch, CEO
- **OcuTerra Therapeutics**  
David Tanzer, CMO and Executive Vice President

### N

- **Nanoscope Therapeutics**  
Aaron Osborne, CMO & CDO
- **Notal Vision**  
Kester Nahen, CEO
- **Novartis Pharma**  
Jill Hopkins, SVP, Global Head Ophthalmology Development

### R

- **REBENXBIO**  
Ram Palanki, SVP, Commercial Strategy & Operations
- **RetinSight**  
Corinna zur Bonsen-Thomas, CEO
- **Re-Vana Therapeutics**  
Michael O'Rourke, CEO

### S

- **Santen Cell and Gene Therapy**  
Marianthi Psacha, Global Head, Cell & Gene Business Segment

### V

- **Visotec**  
Helge Sudkamp, CEO

# Sponsors: RETINA FORUM 2022

THANKS TO THE GENEROSITY OF OUR SPONSORS, THERE IS NO FEE FOR COMPANY PRESENTATIONS AND VIRTUAL REGISTRATION IS COMPLIMENTARY FOR EVERYONE.

## PLATINUM

# Alcon

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Each year our products touch the lives of millions of people living with conditions like cataracts, retinal diseases, and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as differentiated contact lens and lens care portfolio to help patients see, look and feel their best.

At Alcon, we are at the forefront of innovation, partnering with eye care professionals to bring the gift of sight to more people around the world. That's been our legacy for more than 70 years – and as the new Alcon, it's what guides our focus towards the brilliant future ahead.

## GOLD

# Apellis

Apellis is a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines.

At Apellis, we are committed to developing transformative therapies for people living with Geographic Atrophy (GA) by regulating complement, a part of the body's immune system.

Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases such as GA, where there are currently no treatment options available.

For more information about Apellis visit [apellis.com](http://apellis.com) and if you would like to learn more about geographic atrophy, visit [geographicatrophy.eu](http://geographicatrophy.eu).

## SILVER

# EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. Formed in 2018, its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. The Company brings together the complementary expertise of two industry pioneers, one in advanced lens technology and the other in the craftsmanship of iconic eyewear, to set new industry standards for vision care and the consumer experience around it. Influential eyewear brands including Ray-Ban and Oakley, lens technology brands including Varilux and Transitions, and world-class retail brands including Sunglass Hut, LensCrafters, Salmoiraghi & Viganò and GrandVision are part of the EssilorLuxottica family. EssilorLuxottica has approximately 180,000 employees.

# IVERIC BIO

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients' lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit [www.ivericbio.com](http://www.ivericbio.com).

# NOVARTIS

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at <https://www.novartis.com>.

# BAUSCH + LOMB

Each day, we have 14 billion little reminders to continue advancing eye health. From the moment we open our eyes and start to view the possibilities of each new day, we look at how we can improve the well-being of the world's 14 billion eyes. Will this be the day when one of us unlocks a way to eliminate visual impairment in new-borns? Or strikes upon a treatment that actually helps the eye heal itself? To us, these are not some distant hopes. They are the daily questions that add new urgency to all we do and everything we see for the future. We're Bausch + Lomb. One company solely focused on advancing the vision and care of the world's eyes.

# REGENXBIO

REGENXBIO Inc. is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to deliver functional genes, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy has the potential to provide long-lasting effects and improved patient outcomes. We have developed a broad pipeline of gene therapy programs using our NAV® Technology Platform. We believe this platform forms a strong foundation for our current programs, and with our ongoing research and development, we expect to continue to expand the platform.



## BRONZE



AcuFocus, Inc., is a privately held ophthalmic medical device company that delivers breakthrough small aperture intraocular products to address diverse unmet needs and help patients achieve their best personal vision. The IC-8 IOL is a first-of-its-kind presbyopia-correcting lens that delivers true extended depth of focus and enhanced adaptability through its distinctive, wavefront-filtering, small aperture design. The IC-8 IOL received CE mark in 2015 and is available in select markets across Europe and Asia. Visit [www.AcuFocus.com](http://www.AcuFocus.com) for more information.



Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Ireland, Australia, and Asia, and with personnel across over 25 countries to serve clinical sites locally. For over 40 years, Ora has proudly helped clients across the globe earn over 50 product approvals. Ora's unique methodologies and strategies have been proven to maximize the likelihood of success and efficiently bring new products to market. We bring together the world's most experienced ophthalmic experts and operations management to maximize the value of new product initiatives. For more information, visit [www.oraclinical.com](http://www.oraclinical.com).



At Johnson & Johnson Surgical Vision we are passionate about changing the trajectory of eye health and dedicated to partnering with our customers to help more people around the world preserve and restore sight. For over 130 years we have been guided by our CREDO, focusing on improving the lives of the patients and the communities we serve. Our mission is to bring science driven innovation to life through our products and our customer partnerships to elevate eye health for the benefit of all patients. Our commitment to innovation sees us offers a broad range of eye health solutions in ophthalmic care. Our TECNIS® IOL portfolio for example delivers unsurpassed visual outcomes using a combination of proprietary and industry leading optics technologies. We also offer advanced astigmatism management solutions and are a global leader in Refractive Laser Surgery, with an innovative suite of technologies to deliver best in class outcomes.



Théa is the leading independent European pharmaceutical group in ophthalmology. Leader and pioneer in preservative-free treatments, Théa is the unique partner of the eye care professionals for it has constantly been innovating to provide them and their patients with answers to unmet eye care needs. Today, Théa's network includes 1,600 collaborators, and its products are available in 75 countries around the world through its 35 affiliates and partners. In 2021, Théa had global revenues of approximately \$773 million. The independent and family-owned and run group, founded from a R&D start-up by Henri Chibret, has been chaired since 2008 by Jean-Frédéric Chibret. <https://www.laboratoires-thea.com/en>

## NEW INNOVATOR



Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to restore vision to millions of patients with our life-changing regenerative therapies. Our first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells manufactured from a single donor can treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and central corneal thickness. The Aurion Biotech team is preparing for clinical trials in the U.S. To learn more about Aurion Biotech, visit [www.aurionbiotech.com](http://www.aurionbiotech.com)



Oculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address significant unmet medical needs with breakthrough innovations. Oculis's highly differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. With a presence in key international markets, Oculis is poised to deliver life-changing treatments to patients worldwide. Headquartered in Lausanne, Switzerland and with operations in Europe, the U.S. and China, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.



ELIOS Vision, Inc. is a private medical device company headquartered in Los Angeles, CA involved in the commercialisation a novel treatment for glaucoma. The treatment, named ELIOS, safely and effectively lowers IOP and has published outcomes with up to 8yrs of follow-up. ELIOS uses a proprietary laser technology making it reproducible and easy to adopt by comprehensive eye doctors as well as glaucoma specialists. ELIOS is approved for use in EU and is currently undergoing clinical trials for use in the US.



Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for dry eye disease. Nicox generates revenue from VYZULTA® in glaucoma and ZERVIAE® in allergic conjunctivitis, both of which are commercialized by partners.



iSTAR Medical pioneers minimally invasive, ophthalmic implants for safe, meaningful and sustained treatment of glaucoma patients. MINiject® is the only commercially available supraciliary MIGS device and is made from STAR® material, which is soft and flexible, medical-grade, micro-porous silicone enabling bio-integration of surrounding tissues. Clinical trials show that IOP is reduced by 39% to a mean of 14.4mmHg at two years post-surgery. MINiject received CE marking in late 2021 and the US FDA trial (STAR-V) for MINiject is in progress.



A new name in the ophthalmic industry, Medevisé Consulting is composed of individuals with enormous experience in and passion for ophthalmology. Guided by Founder and President Kristine Morrill and our Board of Directors, Medevisé exists to help companies realize their full potential in Europe. We offer an array of innovative services that prepare companies to: meet the challenging and complex questions that arise when developing market access, understand clinical and regulatory procedures, and strategically execute marketing and communications initiatives.

# SAVE THE DATES EURO FORUMS

European Forum: Vienna  
Thurs. 7 September

Retina Forum: Amsterdam  
Weds. 4 October

[ophthalmology-futures.com](https://ophthalmology-futures.com)

Ora

## Meet Ora, the premier strategic partner in Ophthalmic product development

For over 40 years, Ora has proudly helped our clients earn more than 50 product approvals. We support a wide array of organisations, from small start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market.



**2000+ clinical studies and consulting projects**



**25,000+ patients enrolled in last 7 years**



**Extensive, global site network**



**A patient centric philosophy with involvement of patient panels to optimise clinical trial delivery**

Learn how to move your research forward at  
[oraclinical.com](https://oraclinical.com)



**Moorfields Eye Charity supports the incredible and pioneering work of Moorfields Eye Hospital and its research partner, the UCL Institute of Ophthalmology. By supporting innovative research, education and care at these two institutions, we make a difference to the lives of patients at the hospital and people with sight loss around the world.**

To find out more about how you can help support Moorfields, or to make a donation, visit the Moorfields Eye Charity website, contact the charity via email or telephone (020 7566 2565), or drop into our charity office at Moorfields Eye Hospital City Road.

[www.moorfields.nhs.uk/eyecharity](https://www.moorfields.nhs.uk/eyecharity)  
[moorfields.eyecharity@nhs.net](mailto:moorfields.eyecharity@nhs.net)

Registered Charity No.: 1140679

# PROGRAMME COMMITTEE

**Ike Ahmed** | Division Head, Ophthalmology, Trillium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

**Jorge Alio** | Professor & Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Vissum Corporation, Spain.

**Gerd Auffarth** | Professor & Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

**Francesco Bandello** | Full Professor & Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

**David Chang** | Altos Eye Physicians & Clinical Professor, University of California, San Francisco, USA.

**Steve Charles** | Founder & CEO, Charles Retina Institute Clinical Professor of Ophthalmology, University of Tennessee, USA.

**Paul Chew** | Professor of Ophthalmology, National University of Singapore, Singapore.

**Beatrice Cochener** | Professor, Chairman, Ophthalmology Department, University Hospital, Brest, France. Past-president, European Society of Cataract & Refractive Surgeons.

**Jost Jonas** | Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

**Sir Peng Khaw** | Professor of Glaucoma & Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, UK.

**Shigeru Kinoshita** | Professor & Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

**Richard Lindstrom** | Founder & Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

**Boris Malyugin** | Chief of Department of Cataract & Implant Surgery, Deputy Director General, S. Fyodorov Eye Microsurgery Complex State Institution, Moscow, Russia.

**Prof David Spalton** | Past-president, European Society of Cataract & Refractive Surgeons London, UK.

**Prof Dr Ingeborg Stalmans** | Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head, Ophthalmology Research Group, University KU Leuven, Belgium.

**Paulo Eduardo Stanga** | London Vision Clinic Retina Lead Consultant Ophthalmologist & Vitreoretinal Surgeon. Professor of Ophthalmology & Retinal Regeneration, University of Manchester, UK.

**José-Alain Sahel** | Endowed Professor & Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments of Ophthalmology, Quinze-Vingts National Ophthalmology Hospital & Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

**Chelvin Sng** | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

**Julian D. Stevens** | Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

**Donald Tan Tiang Hwee** | Arthur Lim Professor, SNEC & Duke-NUS Medical School, Singapore. Partner & Senior Consultant Ophthalmic Surgeon, Eye & Retina Surgeons (ERS), Camden Medical Centre, Singapore.

**Marie-Jose Tassignon** | Past Chief & Chair Department of Ophthalmology Antwerp University & University Hospital Antwerp, Belgium.

**Adnan Tufail** | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

**Tien Yin Wong** | Founding Head & Chair Professor, Tsinghua University, Beijing, China.

## ADVISORS

**Laurent Attias** | Senior VP, Head of Strategy, BD&L & Market Access, Alcon, USA.

**Christopher Brittain** | Global Head of Ophthalmology, Genentech, Burlingame, USA.

**Arthur Ciociola** | Vice President Global Head Regulatory Affairs GDD Ophthalmology, Devices, & Innovation, Novartis Pharma AG, Fort Worth, USA.

**Eugene de Juan** | Jean Kelly Stock Distinguished Chair, Ophthalmology, ForSight Labs & University of California, Menlo Park, California.

**Tom Dunlap** | Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

**Malvina Eydelman** | Director, Division of Ophthalmic & Ear, Nose & Throat Devices ODE/CDRH/FDA, USA.

**Reza Haque** | SVP and Global Head of OIC, Ophthalmic Innovation Center, Santen Santen Pharmaceutical.

**Paul Hallen** | Vice President & Global Head, Retina, Alcon, Texas, USA.

**Akira Kurokawa** | Chairman, Santen Pharmaceutical Co.

**James Mazzo** | JGlobal President Ophthalmic Devices, Carl Zeiss Meditec, USA.

**Naveed Siddiqi** | Novo Ventures.

## ORGANISING COMMITTEE

**Keith Barton** | Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK, Professor of Ophthalmology, UCL, UK.

**Don Budenz** | Professor & Chairman, Department of Ophthalmology, University of North Carolina, USA.

**Lea Pietrolongo** | Operational Director, Ophthalmology Futures Forums, UK.

**Kuldev Singh** | Professor of Ophthalmology & Director, Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

**Chelvin Sng** | Associate Professor, Department of Ophthalmology, National University Hospital, Singapore.

**Sanny Yuzhen Jiang** | Honorary Clinical Fellow, Moorfields Eye Hospital. Senior Research Associate, University College London Institute of Ophthalmology, UK.





**Apellis is committed to leading** the development of therapies that target the **complement system** with the goal of **slowing GA progression**.

Overactivation of the complement system is strongly associated with the development of lesions in geographic atrophy (GA).<sup>1</sup>

Due to continuous and irreversible vision loss, there is a high unmet need to slow GA lesion progression.<sup>2</sup>

1. Katschke KJ et al. Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy *Sci Rep* 2018;8:13055.

2. Fleckenstein M et al. The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. *Ophthalmology* 2018;125:369-390.

